A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects.

Trial Profile

A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2012

At a glance

  • Drugs HIV vaccine vCP1452 (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 May 2012 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Oct 2009 Results were published in Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top